Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Shionogi Aims at 500 Billion Yen Sales in FY2024: New 5-Year Plan
June 3, 2020
- Kyowa Hakko Bio’s GMP Breach Triggers Shipment Curbs, Stockouts at Astellas, Kowa; Impact Could Reverberate Further
June 3, 2020
- Asahi Kasei Pharma Grabs China Approval for Flivas
June 3, 2020
- Eisai’s Insomnia Med Dayvigo Now Available in US
June 3, 2020
- Fetroja Gets FDA’s Priority Review for Nosocomial Pneumonia
June 3, 2020
- Relugolix Combo Filed in US for Uterine Fibroids
June 3, 2020
- Torii, ASKA to Copromote Riona for Iron Deficiency Anemia
June 2, 2020
- 15 Drug Makers See 3.6% Negative Growth in Japan in FY2020 as Re-Pricing, Generic Entries Weigh: Jiho Tally
June 2, 2020
- Onivyde Now Available in Japan: Servier/Yakult
June 2, 2020
- Daiichi Sankyo to Test TROP2-Directed ADC plus Keytruda in NSCLC
June 2, 2020
- Takeda Launching Project to Gauge Parkinson’s Symptoms with Wearables, Telemedicine Platform
June 2, 2020
- Takeda Gets CHMP Backing for Takhzyro Pre-Filled Syringe
June 2, 2020
- Teva Takeda to Curb Reminyl Generic Supply following June Listing due to India Lockdown
June 2, 2020
- 6 Japan Drug Makers Net 20% Growth in China Biz Despite COVID-19 Woes
June 1, 2020
- Sumitomo Dainippon to Merge Boston Biomedical, Tolero to Streamline Oncology R&D
June 1, 2020
- Top 4 Wholesalers See Higher Operating Profit Rates in FY2019 Driven by Anticancer Agents, Specialty Products
June 1, 2020
- Chugai Files Patent Litigation against Sawai, Nichi-Iko over Edirol Copies
June 1, 2020
- Takeda Winds Up Development of IBD Drug SHP647
June 1, 2020
- JT, Torii File Topical JAK Inhibitor Corectim for Pediatric Atopic Dermatitis
June 1, 2020
- Otsuka’s Q1 Pharma Sales Surge 13% on Global Brands
May 29, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…